Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Integrative metabolic pathway analysis reveals novel therapeutic targets in osteoarthritis

  • Rocha Loureda, Beatriz
  • Cillero-Pastor, B.
  • Eijkel, Gert
  • Calamia, Valentina
  • Fernández-Puente, Patricia
  • Paine, Martin R.L.
  • Ruiz-Romero, Cristina
  • Heeren, Ron M.A.
  • Blanco García, Francisco J
Data availability: The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride/archive/projects/PXD012879) with the dataset identifier PXD012879 and the project name of MSCs OA SILAC Mass spectrometry imaging, [Abstract] In osteoarthritis (OA), impairment of cartilage regeneration can be related to a defective chondrogenic differentiation of mesenchymal stromal cells (MSCs). Therefore, understanding the proteomic- and metabolomic-associated molecular events during the chondrogenesis of MSCs could provide alternative targets for therapeutic intervention. Here, a SILAC-based proteomic analysis identified 43 proteins related with metabolic pathways whose abundance was significantly altered during the chondrogenesis of OA human bone marrow MSCs (hBMSCs). Then, the level and distribution of metabolites was analyzed in these cells and healthy controls by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI), leading to the recognition of characteristic metabolomic profiles at the early stages of differentiation. Finally, integrative pathway analysis showed that UDP-glucuronic acid synthesis and amino sugar metabolism were downregulated in OA hBMSCs during chondrogenesis compared with healthy cells. Alterations in these metabolic pathways may disturb the production of hyaluronic acid (HA) and other relevant cartilage extracellular matrix (ECM) components. This work provides a novel integrative insight into the molecular alterations of osteoarthritic MSCs and potential therapeutic targets for OA drug development through the enhancement of chondrogenesis., This work has been funded by Fondo Investigación Sanitaria-Spain (grant numbers PI14/01707, PI16/02124, PI17/00404, DTS17/00200, CIBER-CB06/01/0040 and RETIC-RIER-RD12/0009/0018), a part of the National Plan for Scientific Program Development and Technological Innovation 2013–2016, funded by the ISCIII-General Subdirection of Assessment and Promotion of Research - European Regional Development Fund (FEDER) “A way of making Europe.” The Proteomics Unit of GIR belongs to ProteoRed, PRB2- ISCIII (grant number PT17/0019/0014). B.R. is supported by Xunta de Galicia (IN606B-2016/004). The research was partially performed within the M4I research program, financially supported by the Dutch Province of Limburg as part of the “LINK” program, Xunta de Galicia; IN606B-2016/004, https://www.ebi.ac.uk/pride/archive/projects/PXD012879
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Mass spectrometry imaging: A novel technology in rheumatology

  • Rocha Loureda, Beatriz
  • Ruiz-Romero, Cristina
  • Blanco García, Francisco J
Review, [Abstract] Mass spectrometry imaging (MSI) is used to determine the relative abundance and spatial distribution of biomolecules such as peptides, proteins, lipids and other organic compounds in tissue sections by their molecular masses. This technique provides a sensitive and label-free approach for high-resolution imaging, and is currently used in an increasing number of biomedical applications such as biomarker discovery, tissue classification and drug monitoring. Owing to technological advances in the past 5 years in diverse MSI strategies, this technology is expected to become a standard tool in clinical practice and provides information complementary to that obtained using existing methods. Given that MSI is able to extract mass-spectral signatures from pathological tissue samples, this technique provides a novel platform to study joint-related tissues affected by rheumatic diseases. In rheumatology, MSI has been performed on articular cartilage, synovium and bone to increase the understanding of articular destruction and to characterize diagnostic and prognostic biomarkers for osteoarthritis, rheumatoid arthritis and osteoporosis. In this Review, we provide an overview of MSI technology and of the studies in which joint tissues have been analysed by use of this methodology. This approach might increase knowledge of rheumatic pathologies and ultimately prompt the development of targeted strategies for their management., This work is funded by grants from Fondo Investigación Sanitaria-Spain (PI12/00329, PI14/01707, CIBER‑CB06/01/0040, RETICRIER‑RD12/0009/0018). B.R. is funded by Xunta de Galicia (IN606B‑2016/004), and C.R.R. by the Miguel Servet II program from Fondo Investigación Sanitaria-Spain (CPII15/0013). The Proteomics Unit belongs to ProteoRed, PRB2‑ISCIII, supported by grant PT13/0001.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Screening and validation of novel biomarkers in osteoarticular pathologies by comprehensive combination of protein array technologies

  • Sierra-Sánchez, Álvaro
  • Garrido-Martín, Diego
  • Lourido, Lucía
  • González-González, María
  • Díez, Paula
  • Ruiz-Romero, Cristina
  • Sjöberg, Ronald
  • Droste, Conrad
  • De Las Rivas, Javier
  • Nilsson, Peter
  • Blanco García, Francisco J
  • Fuentes, Manuel
[Abstract] Osteoarthritis (OA) is one of the most prevalent articular diseases. The identification of proteins closely associated with the diagnosis, progression, prognosis, and treatment response is dramatically required for this pathology. In this work, differential serum protein profiles have been identified in OA and rheumatoid arthritis (RA) by antibody arrays containing 151 antibodies against 121 antigens in a cohort of 36 samples. Then the identified differential serum protein profiles have been validated in a larger cohort of 282 samples. The overall immunoreactivity is higher in the pathological situations in comparison with the controls. Several proteins have been identified as biomarker candidates for OA and RA. Most of these biomarker candidates are proteins related to inflammatory response, lipid metabolism, or bone and extracellular matrix formation, degradation, or remodeling., We gratefully acknowledge financial support from the Carlos III Health Institute of Spain (ISCIII, FIS PI14/01538, PI12/00624, PI12/00329, PI14/01707, CIBER-CB06/01/0040, and RETIC-RIER-RD12/0009/0018), Fondos FEDER (EU), Junta Castilla y León (BIO/SA07/15), and Fundación Solórzano (FS-23-2015). The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by Grant No. PT13/0001 (ISCIII-Fondos FEDER). P.D. and C.D. are supported by a JCYL-EDU/346/2013 Ph.D. scholarship. The work of D.G.M. was supported by a collaboration scholarship (BOE-A-2014-3844) from the Spanish Ministry of Education, Culture, and Sports (MECD) and awarded in the XIII Certamen Universitario Arquímedes (BOE-A-2014-12688, MECD). We also thank Javier Martín Vallejo and Manuel Muñoz Aguirre for useful discussions and statistical support.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Lessons from the proteomic study of osteoarthritis

  • Ruiz-Romero, Cristina
  • Fernández-Puente, Patricia
  • Calamia, Valentina
  • Blanco García, Francisco J
Review, [Abstract] Osteoarthritis is the most common rheumatic pathology and one of the leading causes of disability worldwide. It is a very complex disease whose etiopathogenesis is not fully understood. Furthermore, there are serious limitations for its management, since it lacks specific and sensitive biomarkers for early diagnosis, prognosis and therapeutic monitoring. Proteomic approaches performed in the last few decades have contributed to the knowledge on the molecular mechanisms that participate in this pathology and they have also led to interesting panels of putative biomarker candidates. In the next few years, further efforts should be made for translating these findings into the clinical routines. It is expected that targeted proteomics strategies will be highly valuable for the verification and qualification of biomarkers of osteoarthritis., This work is funded by grants from Fondo Investigación Sanitaria-Spain (PI11/02397, PI12/00329 and PI14/01707). C. Ruiz-Romero is supported by the Miguel Servet program from Fondo Investigación Sanitaria, Spain (CP09/00114).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Defining the proteomic landscape of rheumatoid arthritis: progress and prospective clinical applications

  • Lourido Salas, Lucía María
  • Blanco García, Francisco J
  • Ruiz-Romero, Cristina
Review, [Abstract] The heterogeneity of Rheumatoid Arthritis (RA) and the absence of clinical tests accurate enough to identify the early stages of this disease have hampered its management. Therefore, proteomics research is increasingly focused on the discovery of novel biological markers, which would not only be able make an early diagnosis, but also to gain insight into the different pathological mechanisms underlying the heterogeneity of RA and also to stratify patients, which is critical to enabling effective treatments. Areas covered: The proteomic approaches that have been utilised to provide knowledge about RA pathogenesis, and to identify biomarkers for RA diagnosis, prognosis, disease monitoring and prediction of response to therapy, are summarized. Expert commentary: Although each proteomic study is unique in its design, all of them have contributed to the understanding of RA pathogenesis and the discovery of promising biomarkers for patient stratification, which would improve clinical care of RA patients. Still, efforts need to be made to validate these findings and translate them into clinical practice., The authors were supported by grants from Fondo Investigación Sanitaria- Spain (PI16/02124, PI14/01707, CIBER-CB06/01/0040, RETIC-RIER-RD12/ 0009/0018). L. Lourido is funded by Xunta de Galicia (IN606B-2016/005), and C. Ruiz-Romero by the Miguel Servet II program from Fondo Investigación Sanitaria-Spain (CPII15/0013). The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Multiplexed mass spectrometry monitoring of biomarker candidates for osteoarthritis

  • Fernández-Puente, Patricia
  • Calamia, Valentina
  • González-Rodríguez, Lucía
  • Lourido, Lucía
  • Camacho Encina, María
  • Oreiro Villar, Natividad
  • Ruiz-Romero, Cristina
  • Blanco García, Francisco J
[Abstract] The methods currently available for the diagnosis and monitoring of osteoarthritis (OA) are very limited and lack sensitivity. Being the most prevalent rheumatic disease, one of the most disabling pathologies worldwide and currently untreatable, there is a considerable interest pointed in the verification of specific biological markers for improving its diagnosis and disease progression studies. Considering the remarkable development of targeted proteomics methodologies in the frame of the Human Proteome Project, the aim of this work was to develop and apply a MRM-based method for the multiplexed analysis of a panel of 6 biomarker candidates for OA encoded by the Chromosome 16, and another 8 proteins identified in previous shotgun studies as related with this pathology, in specimens derived from the human joint and serum. The method, targeting 35 different peptides, was applied to samples from human articular chondrocytes, healthy and osteoarthritic cartilage, synovial fluid and serum. Subsequently, a verification analysis of the biomarker value of these proteins was performed by single point measurements on a set of 116 serum samples, leading to the identification of increased amounts of Haptoglobin and von Willebrand Factor in OA patients. Altogether, the present work provides a tool for the multiplexed monitoring of 14 biomarker candidates for OA, and verifies for the first time the increased amount of two of these circulating markers in patients diagnosed with this disease. Significance: We have developed an MRM method for the identification and relative quantification of a panel of 14 protein biomarker candidates for osteoarthritis. This method has been applied to analyze human articular chondrocytes, articular cartilage, synovial fluid, and finally a collection of 116 serum samples from healthy controls and patients suffering different degrees of osteoarthritis, in order to verify the biomarker usefulness of the candidates. HPT and VWF were validated as increased in OA patients., This work was funded by grants from Fondo Investigación Sanitaria-Spain (PI12/00329, PI14/01707, CIBER-CB06/01/0040, RETIC-RIER-RD12/0009/0018). C.R.-R. is supported by the Miguel Servet II program from Fondo Investigación Sanitaria-Spain (CPII15/00013). The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

MALDI mass spectrometry imaging in rheumatic diseases

  • Rocha Loureda, Beatriz
  • Cillero-Pastor, B.
  • Blanco García, Francisco J
  • Ruiz-Romero, Cristina
Review, [Abstract] Mass spectrometry imaging (MSI) is a technique used to visualize the spatial distribution of biomolecules such as peptides, proteins, lipids or other organic compounds by their molecular masses. Among the different MSI strategies, MALDI-MSI provides a sensitive and label-free approach for imaging of a wide variety of protein or peptide biomarkers from the surface of tissue sections, being currently used in an increasing number of biomedical applications such as biomarker discovery and tissue classification. In the field of rheumatology, MALDI-MSI has been applied to date for the analysis of joint tissues such as synovial membrane or cartilage. This review summarizes the studies and key achievements obtained using MALDI-MSI to increase understanding on rheumatic pathologies and to describe potential diagnostic or prognostic biomarkers of these diseases. This article is part of a Special Issue entitled: MALDI Imaging, edited by Dr. Corinna Henkel and Prof. Peter Hoffmann., This work was funded by grants from Fondo Investigación Sanitaria-Spain (PI12/00329, PI14/01707, CIBER-CB06/01/0040, RETIC-RIER-RD12/0009/0018). C.R.-R. is supported by the Miguel Servet II program from Fondo Investigación Sanitaria-Spain (CPII15/00013). The Proteomics Unit belongs to ProteoRed, PRB2- ISCIII, supported by grant PT13/0001.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Secretome analysis of human articular chondrocytes unravels catabolic effects of nicotine on the joint

  • Lourido Salas, Lucía María
  • Calamia, Valentina
  • Fernández-Puente, Patricia
  • Mateos, Jesús
  • Oreiro Villar, Natividad
  • Blanco García, Francisco J
  • Ruiz-Romero, Cristina
[Abstract] Purpose: Osteoarthritis (OA) is a degenerative joint pathology characterized by articular cartilage degradation that lacks from efficient therapy. Since previous epidemiological data show a high controversy regarding the role of smoking in OA, we aimed to evaluate the effects of nicotine (the most physiologically active compound of tobacco) on the joint. Experimental design: Secretome analyses, based on metabolic labeling followed by LC-MALDI-TOF/TOF analysis, were carried out using an in vitro model of articular inflammation (primary human articular chondrocytes treated with interleukin-1β), and also on osteoarthritic cells. ELISA and Western blot assays were performed to verify some of the results. Results: Nineteen proteins were altered by nicotine in the model of articular inflammation, including several cytokines and proteases. We confirmed the increased secretion by nicotine of matrix metalloproteinase 1 and two proposed markers of OA, fibronectin, and chitinase 3-like protein 1. Finally, four components of the extracellular matrix of cartilage were decreased by nicotine in OA chondrocytes. Conclusions and clinical relevance: Our data contribute to a better understanding of the molecular mechanisms that are modulated by nicotine in cartilage cells, suggesting a negative effect of this drug on the joint., This study was supported by grants from Fondo Investigación Sanitaria-Spain (CP09/00114, PI11/02397, PI12/00329, PI14/01707, CIBER-CB06/01/0040, RETIC-RIER-RD12/0009/0018, and Proteo-Red/ISCIII) and Xunta de Galicia (10CSA916058PR, 10PXIB310153PR, REDICENT and REGICC). L.L. was supported by Xunta de Galicia. C. R.-R. is supported by Fondo Investigación Sanitaria-Spain (Miguel Servet program, CP09/00114).